Resorcinol

Resorcinol

SCHEMBL3799798

C1CCCCC1.Oc1cccc(O)c1

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.80
CA12 O43570 4/20 0.80
CA2 P00918 4/20 0.80
CA9 Q16790 4/20 0.80
CA14 Q9ULX7 3/20 0.80
CYP3A4 P08684 2/20 0.80
LMNA P02545 1/20 0.80
CA5A P35218 1/20 0.80
HSD17B10 Q99714 1/20 0.80
CA5B Q9Y2D0 1/20 0.80
HSD17B1 P14061 3/20 0.52
HSD17B2 P37059 3/20 0.52
CA1 P00915 3/20 0.52
TSHR P16473 2/20 0.52
ACHE P22303 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
CYP2C9 P11712 1/20 0.52
CA7 P43166 1/20 0.52
LCK P06239 1/20 0.50
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Resorcinol SCHEMBL15515 0.89
Resorcinol SCHEMBL326229 0.89 CA12 (1.00) ALDH1A1CA12CA2CA9CA14
Resorcinol SCHEMBL8442393 0.86
Resorcinol SCHEMBL5867187 0.86
Resorcinol SCHEMBL3984288 0.86 CA12 (0.92) ALDH1A1CA12CA2CA9CA14
Resorcinol SCHEMBL971994 0.86
Resorcinol SCHEMBL11679916 0.86 CA12 (0.92) ALDH1A1CA12CA2CA9CA14
Resorcinol SCHEMBL563023 0.86 CA12 (0.92) ALDH1A1CA12CA2CA9CA14
Resorcinol SCHEMBL20577903 0.86
Resorcinol SCHEMBL8829963 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1572798-B1 RUBBER COMPOSITIONS AND ARTICLES THEREOF HAVING IMPROVED METAL ADHESION AND METAL ADHESION RETENTION WITH BRIGHT STEEL BRIDGESTONE AMERICAS TIRE (US) 2010-02-17 EP disclosed
US-7285687-B2 Cannabinoids VIRGINIA COMMONWEALTH UNIVERSITY (US) 2007-10-23 US disclosed
US-7201944-B2 Rubber compositions and articles thereof having improved metal adhesion and metal adhesion retention with bright steel BRIDGESTONE FIRESTONE NORTH AMERICAN TIRE, LLC (US) 2007-04-10 US disclosed
US-7179800-B2 Such as 2-(3-methylcyclohexyl)-5-(1,1'-dimethylheptyl)-resorcinol for treatment of pain, inflammation and autoimmune disease VIRGINIA COMMONWEALTH UNIVERSITY (US) 2007-02-20 US disclosed
US-20070037890-A1 Such as 2-(3-methylcyclohexyl)-5-(1,1'-dimethylheptyl)-resorcinol for treatment of pain, inflammation and autoimmune disease VIRGINIA COMMONWEALTH UNIVERSITY (US) 2007-02-15 US disclosed
EP-1572798-A1 RUBBER COMPOSITIONS AND ARTICLES THEREOF HAVING IMPROVED METAL ADHESION AND METAL ADHESION RETENTION WITH BRIGHT STEEL Bridgestone/Firestone North American Tire, LLC (US) 2005-09-14 EP disclosed
US-20050165259-A1 Such as 2-(3-methylcyclohexyl)-5-(1,1'-dimethylheptyl)-resorcinol for treatment of pain, inflammation and autoimmune disease VIRGINIA COMMONWEALTH UNIVERSITY (US) 2005-07-28 US disclosed
US-20050159449-A1 Cannabinoids VIRGINIA COMMONWEALTH UNIVERSITY (US) 2005-07-21 US disclosed
US-20050119383-A1 Rubber compositions and articles thereof having improved metal adhesion and metal adhesion retention with bright steel BRIDGESTONE/FIRESTONE NORTH AMERICAN TIRE, LLC 2005-06-02 US disclosed
WO-2004058871-A1 RUBBER COMPOSITIONS AND ARTICLES THEREOF HAVING IMPROVED METAL ADHESION AND METAL ADHESION RETENTION WITH BRIGHT STEEL BRIDGESTONE/FIRESTONE NORTH AMERICAN TIRE, LLC (US) 2004-07-15 WO disclosed
WO-2003091189-A1 CANNABINOIDS VIRGINIA COMMONWEALTH UNIVERSITY (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165259-A1 Such as 2-(3-methylcyclohexyl)-5-(1,1'-dimethylheptyl)-resorcinol for treatment of pain, inflammation and autoimmune disease CNR1, CNR2, HRH4 ALDH1A1 3786/4885CA12 3993/4885CA2 3275/4885
US-20050159449-A1 Cannabinoids CNR1, CNR2, OPRL1 ALDH1A1 3865/4885CA12 3094/4885CA2 2453/4885
US-20070037890-A1 Such as 2-(3-methylcyclohexyl)-5-(1,1'-dimethylheptyl)-resorcinol for treatment of pain, inflammation and autoimmune disease CNR1, CNR2, HRH4 ALDH1A1 3786/4885CA12 3993/4885CA2 3275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.